For years, the annual hypertension review has followed a familiar, exhaustive script. BP, weight, heigh, lifestyle and almost reflexively, we order a "standard" battery of bloods; FBC, U&Es, LFTs, Lipids, maybe even a Thyroid panel "just in case." We’ve been casting a wide net, but in January 2026, the evidence suggests we’ve been catching mostly "noise."
The conflict: Across UK primary care, variation in monitoring has become a silent burden. Some practices test everything, others under-test, and the resulting "over-monitoring" leads to a cascade of anxiety for patients and an afternoon of filing "normal/no action" results. We’ve been looking for haystacks that don't exist, often at the expense of limited NHS phlebotomy appointments and laboratory resources.
The resolution: A consensus study published on 6 January 2026 in the British Journal of General Practice (BJGP) has introduced a new philosophy: Diagnostic Elegance. By synthesising rapid reviews and primary care data, researchers have identified a "minimal set" of evidence-based tests that truly move the clinical needle.
The “core four tests”
The study has stripped the panel back to its most essential elements. For a stable patient with hypertension, the evidence now suggests focusing on just four markers:
1. eGFR: To catch the early, silent drift into Chronic Kidney Disease.
2. HbA1c: To screen for the common "partner in crime" of hypertension, Type 2 Diabetes.
3. Potassium: Critical for those on ACE inhibitors or ARBs.
4. Sodium: Essential for monitoring those on thiazide-type diuretics.
The researchers found no consistent evidence that routine monitoring of liver function (LFTs), full blood counts (FBC), or thyroid function provides any clinical benefit for an asymptomatic, stable hypertensive patient.
While lipids remain vital for initial QRISK3 assessment, the authors suggest they do not require automatic annual repetition in stable, asymptomatic patients already on optimal statin therapy or those with a low risk profile. ACR testing should be focused on those with evidence of target organ damage or diabetes, rather than being a "standard" for every uncomplicated Stage 1 patient.
The authors note that new guidance and local protocols need to make clear that additional tests can be added if clinically indicated, but should not be included for routine monitoring purposes. Educating staff requesting tests about the harms of over-testing may help avoid tests being added “just in case” or “because we have always done this”.
